Novacyt (LON:NCYT) Shares Down 2.3% – Here’s Why

Novacyt S.A. (LON:NCYT)’s stock price traded down 2.3% on Monday . The stock traded as low as GBX 43 and last traded at GBX 43. 11,069 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 183,070 shares. The stock had previously closed at GBX 44.

Novacyt Trading Down 0.6%

The stock has a market cap of £30.28 million, a price-to-earnings ratio of -1.30 and a beta of 1.11. The business has a 50-day simple moving average of GBX 40.69 and a two-hundred day simple moving average of GBX 38.53. The company has a debt-to-equity ratio of 44.74, a current ratio of 4.74 and a quick ratio of 4.46.

About Novacyt

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.